Hemophagocytic lymphohistiocytosis secondary to visceral leishmaniasis in an endemic area in the north of Minas Gerais, Brazil

Fernando Henrique Guimarães de Carvalho[1], Jamille Fernandes Lula[1], Leandro de Freitas Teles[1,3], Antônio Prates Caldeira[1] and Silvio Fernando Guimarães de Carvalho[1,2]

[1]. Unimontes, Hospital Universitário Clemente de Faria, Montes Claros, MG, Brasil.
[2]. Unimontes, Departamento de Saúde da Mulher e da Criança, Montes Claros, MG, Brasil.
[3]. Fundação Hemominas, Montes Claros, MG, Brasil.

Abstract

Introduction: Visceral leishmaniasis (VL) is an ill-studied disease that is endemic to several regions of Brazil. It is often complicated by hemophagocytic lymphohistiocytosis (HLH), a potentially fatal disorder resulting from excessive non-malignant activation/proliferation of T lymphocytes and macrophages. Considering the overlapping clinical and laboratory characteristics of these diseases, diagnosing HLH is a challenge. Therefore, tracking the association between VL and HLH is necessary in endemic areas. Although HLH can be inapparent and resolve with antileishmanicides, this may not always occur. HLH causes high lethality; therefore, immunosuppressive therapy should be instituted immediately in order to avoid a fatal outcome.

Methods: We described the epidemiological, clinical, laboratory, and therapeutic profile of this association in a region of Brazil endemic for VL.

Results: We presented 39 patients with this association in a retrospective cohort of 258 children who were admitted from January 2012 to June 2017. Of the 39 patients, 31 were from urban areas (79.5%), and 21 (53%) were males. The mean age and weight were 2.86 (2.08) years and 14.03 (5.96) kg, respectively. The main symptoms were fever (100%), hepatosplenomegaly (100%), pallor of the skin and mucosa (82.5%), edema (38.5%), bleeding (25%), and jaundice (7.5%). Hemophagocytosis was identified in 16/37 (43.24%) patients, and direct examination revealed that 26/37 (70.27%) patients were positive for VL. The patients were treated as recommended by the Ministry of Health.

Conclusions: It was observed that HLH is a common complication in endemic areas, and its diagnosis must consider the overlapping of clinical characteristics and pancytopenia.

Keywords: Visceral Leishmaniasis. Hemophagocytic lymphohistiocytosis. Hemophagocytic syndrome.

INTRODUCTION

Visceral leishmaniasis (VL) is a public health concern in developing countries. The overall annual incidence has been estimated at approximately 200,000 to 400,000 cases, with a mortality rate of 10% per year[1]. In Brazil, VL is a zoonosis caused by Leishmania infantum, with the domestic dog serving as the main reservoir and Lutzomyia longipalpis (sand fly) as the vector of greater epidemiological importance. More than 95% of the reported cases of VL in Latin America occur in Brazil, in more than 40% of children aged less than 10 years. The occurrence of VL is rapidly increasing, and concomitantly, there is an increase in its lethality, despite the currently available therapeutic options[2]. Patients with fever for a period ≥ 7 days, along with splenomegaly or hepatosplenomegaly, pallor of the skin and mucosa, and pancytopenia or peripheral bicytopenia are suspected of harboring the disease.

Hemophagocytic lymphohistiocytosis (HLH), or hemophagocytic syndrome (HPS), poses a significant diagnostic and therapeutic challenge. According to the Histiocyte Society[3,4], there are two types of HLH, namely, the primary or genetic form, also known as familial HLH, and a secondary or acquired form[5,6], which occurs in patients with no family history or known genetic cause for the syndrome. Five of the eight criteria should be present to establish the diagnosis and initiate treatment (Figure 1).
A. Molecular diagnosis compatible with hemophagocytic lymphohistiocytosis or
B. At least five of the following eight criteria:
   1. Fever \( \geq 38.5^\circ C \) for a period \( \geq 7 \) days.
   2. Splenomegaly.
   3. Cytopenias (two or more lineages)
      a. Hemoglobin <9 g/dL or <10 g/dL in newborns
      b. Platelets < 100 x 10^9/L
      c. Neutrophils <1,0 x 10^9/L
   4. Hypertriglyceridemia or hypofibrinogenemia
      a. Triglycerides >265 mg/dL
      b. Fibrinogen < 150 mg/dL
   5. Hemophagocytosis in the bone marrow, spleen, lymph nodes, or liver, with no evidence of malignancy
   6. Decrease or absence of natural killer cell activity
   7. Serum ferritin > 500 µg/L
   8. Increased soluble CD25 \( \geq 2400 \) U/mL

FIGURE 1: Criteria for the diagnosis of hemophagocytic lymphohistiocytosis. 
Source: Histiocyte Society—Treatment Protocol of The Second International HLH Study 2004.

HLH findings include persistent fever, hepatosplenomegaly, hypertriglyceridemia, hypofibrinogenemia, hyperferritinemia, cytopenia, liver dysfunction, decreased natural killer cell (NK) and IL-2 receptor (soluble r-CD25) activity, and the presence of hemophagocytosis in the bone marrow, spleen, and liver\(^6,7\). It is a potentially fatal disorder resulting from excessive non-malignant activation/proliferation of T lymphocytes and macrophages. Viral, bacterial, fungal, and parasitic infections, as well as autoimmune and neoplastic diseases, can trigger this disorder\(^6\).

The literature considers VL/HLH association a rare occurrence. The first case of VL/HLH occurred in Greece in 1984, and by December 2012, forty-five pediatric cases had been described, with a mortality rate of 13.5%\(^8\). Given the scarcity of data in the literature, this retrospective study aimed at describing the clinical and laboratory presentations of VL, complicated with HLH, in children monitored at the Pediatrics Department of the University Hospital, Montes Claros State University (HU-UNIMONTES) between January 2012 and June 2017.

METHODS

Study design

This was a retrospective study of patients with an association between VL and HLH.

Location, data source, and study period

The study was conducted at the Clemente de Faria University Hospital (HUCF) of the Montes Claros State University, which is the only reference hospital for the treatment of infectious and contagious diseases, including VL, in the entire northern region of Minas Gerais.

The data was collected from the medical records of children between the ages of zero and twelve years, who were admitted to the HUCF from January 2012 to June 2017 with a diagnosis of VL.

Ethical considerations

The study followed all ethical precepts and was conducted in accordance with the principles laid in resolution 466/12. The study protocol was approved by the Ethics Committee of the Montes Claros State University, Process No. 2050, and the institution authorized data collection.

Diagnostic tests

Patients who presented with the clinical disease (fever for a period \( \geq 7 \) days, splenomegaly or hepatosplenomegaly, and pallor of the skin and mucusa) with pancytopenia or peripheral bicytopenia were suspected to have a diagnosis of VL. The diagnosis was confirmed with the confirmation of *Leishmania* in the smear of the bone marrow aspirate and/or a rapid positive test for VL (Kalazar Detect\(^*\), InBios, Seattle and IT Leish\(^*\), Bio-Rad, Marnes-la-Coquette).

The presence of at least five of the six investigated criteria established by the Lymphohistiocytosis Hemophagocytic Study Group in 2004 was considered for the diagnosis of HLH\(^9\).

Concept of cure

‘Cure’ was defined as complete remission of clinical signs and symptoms, associated with the normalization of changes in laboratory parameters observed at baseline, without evidence of recurrence in twelve months.

Study variables

The demographic variables described were age, gender, and origin (rural or urban). The clinical variables were fever, hepatomegaly, splenomegaly, pallor, hemorrhage, jaundice, edema, nutritional status, presence of co-infections, time of disease onset, and discharge conditions. Laboratory variables were represented by blood count, platelet count, prothrombin activity, CRP (C-reactive
protein), hemophagocytosis imaging research, direct examination of bone marrow aspirate and rapid tests for VL (Kalazar Detect® and IT Leish®), and HIV (HIV Tri Line - K087®, Bioclin, Belo Horizonte). The levels of bilirubin, transaminases, amylase, lipase, urea, creatinine, triglycerides, ferritin, total proteins, and fractions were also estimated. The specific treatments used for VL were N-methylglucamine Antimony 20 mg.kg⁻¹.day⁻¹ for 20 consecutive days, Amphotericin B deoxycholate 1 mg.kg⁻¹.day⁻¹ for 14 consecutive days, and liposomal Amphotericin B 3 mg.kg⁻¹.day⁻¹ for 7 consecutive days or 4 mg.kg⁻¹.day⁻¹ for 5 consecutive days. Additional treatments, such as corticotherapy, antibiotic therapy, and blood components, were also identified. Image examinations were performed in the indicated cases.

A standardized study questionnaire, developed by a group of researchers, was used to collect data from each patient.

**Statistical analysis**

Statistical analysis was performed using SPSS for Windows, version 18.0 (SPSS Inc., Chicago, IL, USA).

**RESULTS**

During the study period (January 2012 to June 2017) 258 children aged 9 years or younger, with a diagnosis of VL, were admitted to the Clemente de Faria University Hospital, Montes Claros State University—UNIMONTES. Among these 258 children, 39 (15.1%) met the diagnostic criteria of having an association between VL and HLH, and thirty-one out of 39 children with a VL/H LH association were from urban areas (79.5%). All patients lived in the north of the state of Minas Gerais, and the majority were from the city of Montes Claros. The mean age of the patients was 2.86 (2.08) years (ranging from five months old to nine years and two months old), with a median of two years and one month, and 90% of the patients were younger than five years old. Among 39 patients, 21 (53%) were males. The mean weight at admission was 14.03 (5.96) kg (ranging from 6.4 kg to 28 kg), with a median of 12 kg. Although no cases of malnutrition were identified, overweight cases were observed.

The primary signs and symptoms at admission were fever (100%), splenomegaly and hepatomegaly (100%), pallor of the skin and mucosa (82.5%), edema of any intensity (38.5%), bleeding in one or more sites (25%), and jaundice (7.5%). Petechiae, ecchymosis, hemorrhagic suffusions, gingival bleeding, and enterorrhagia, isolated or associated, were present in 10 (25.64%) patients.

Laboratory findings at admission showed low levels of hemoglobin 6.82 (1.36) g/dL, leukocytes 3.722 (1.472) /mm³, neutrophils 1,161 (671) /mm³, platelets 58,384 (30,536) /mm³, and prothrombin activity 73.65 (17.81) %. High levels of ferritin 1,497 (380.53) IU/L, GPT- glutamic-oxaloacetic transaminase 245.58 (1,550) IU/L, GPT- glutamic-oxaloacetic transaminase 110.33 (177.79) IU/L, total bilirubin 0.75 (0.72) mg/dL, direct bilirubin 0.35 (0.46) mg/dL, and indirect bilirubin 0.39 (0.33) mg/dL were observed.

Other estimated values were total protein: 6.47 (1.33 ) g/dL; albumin: 2.98 (0.47) g/dL; globulins: 3.59 (1.00) g/dL; creatinine: 0.49 (0.14) mg/dL; urea: 21.81 (7.09) mg/dL; amylase: 42.10 (22.54) IU/L; lipase: 32.23 (25.68) IU/L; potassium: 4.18 (0.53) mEq/L, and sodium: 134.12 (3.83) mEq/L. No electrocardiographic changes were observed on the admission exams.

The microscopic examination of the bone marrow showed hemophagocytosis in 16/37 (43.24%) patients who were subjected to aspiration puncture. Two patients were not subjected to bone marrow biopsy due to the absence of a hematologist at the time of the procedure.

Specific tests for the diagnosis of VL were also performed. Among 37 patients, the direct test was positive in 26 (70.3%) patients, negative in 11 (29.72%) patients, and was not performed in two (5.12%) patients. Rapid tests for VL, Kalazar Detect®, or IT Leish® were positive in 32/34 (94.11%) patients, negative in 2/34 (5.88%), and not performed in 5/39 (12.82%) patients.

Antibiotic therapy was used in 31/39 (79.5%) patients, being empirical in 22/39 (56.4%) patients and specific in 9/39 (23.1%) patients; there were 4 patients with pneumonia, 3 with acute otitis media, and 2 with sepsis and disseminated intravascular coagulation (DIC).

Blood component transfusions were used in 19/39 (48.7%) of patients; 18/39 (46.2%) patients received red blood cell (RBC) transfusions, 7/39 (36.8%) received platelet transfusions, and 3/39 (15.8%) also required fresh frozen plasma.

Corticotherapy was used in 15/39 patients (38.5%), and dexamethasone, associated with treatment for VL, was prescribed as a therapy for HLH. Anti-inflammatory doses were used in 9/15 patients (60%) and immunosuppressive doses, in 6/15 (40%) patients. Among the 15 patients who used corticosteroids, 6 (40%) were younger than two years old (2 received immunosuppressive doses), and 9 (60%) were older than two years (4 received immunosuppressive doses). The age of the group of patients using corticotherapy ranged from five months to six years and one month.

Dexamethasone at the dose of 10 mg/m² of body surface was used in cases of immunosuppression. Two patients used it for eight weeks, three for six weeks, and one for four weeks. The prescribed anti-inflammatory dose was 0.22 mg.kg⁻¹.day⁻¹ for seven days.

All patients were negative for the rapid HIV test and were given specific treatment for VL for the first time.

N-methylglucamine antimony administration was the first choice in 18/39 (46.1%) patients, out of which, 10 (25.6%) were cured, and 8 (20.5%) had their treatment interrupted (5 patients (12.8%) due to non-therapeutic response and 3 (7.7%) due to adverse effects. Amphotericin B deoxycholate was prescribed for one patient with a good therapeutic response.

Liposomal Amphotericin B was prescribed as the first option in 20/39 (51.3%) patients: 12/39 (30.8%) patients were administered with 4 mg.kg⁻¹.day⁻¹ for five consecutive days, and 8/39 (20.5%) patients were administered with 3 mg.kg⁻¹.day⁻¹ for seven consecutive days. All these patients were cured, but one patient in the 3 mg.kg⁻¹.day⁻¹ group had his treatment extended for an additional 7 days.

The rescue treatment for VL, with the use of liposomal amphotericin B, was performed in all patients who were not...
cured. Six patients were administered with 4 mg.kg⁻¹.day⁻¹ for five consecutive days, and two patients were administered with 3 mg.kg⁻¹.day⁻¹ for seven days; all 8 of these patients have been cured.

After treatment, all patients were followed up in outpatient clinics for twelve months. Consultations were held in the second, sixth, and twelfth month after treatment or at any time when deemed necessary. The record of follow-ups showed that all the patients were cured at the end of twelve months (Table 1).

The mean time between the onset of symptoms and admission was 23.72 (22.8) days, with fever reported by all patients as the initial symptom of the disease. The mean hospital stay was 17.74 (5.7) days (ranging from 7 days to 29 days).

**DISCUSSION**

Several tropical infections associated with HLH are rapidly increasing. The clinical findings of VL overlap with those of HLH, and using the diagnosis of leishmaniasis as a trigger for the syndrome can be challenging, even in endemic areas. Consequently, the delay in the diagnosis of HLH associated with VL, likely due to clinical similarities, can cause severe complications and death in up to 90% of patients without specific treatment for HLH. HLH associated with VL rarely occurs in childhood, with less than 50 cases reported in the literature until 2012. This finding is corroborated by Bode et al., who found a 2.1% prevalence of HLH in German patients with VL, mainly in children. Even in India, which accounts for 90% of the cases of VL worldwide, this association has been reported as rare. The same is true for other countries such as Tunisia, Turkey, Sudan, and Iran, with most of the studies being case reports.

However, the prevalence in Brazil is high. Daher et al. found 35 pediatric patients with HLH among 127 (27.5%) participants with VL in an endemic area in the Northeast region of the country.

The present study, until the most recent literature review on the subject, has the highest number of reported cases. Conducted in an endemic area in the north of the state of Minas Gerais, it found a prevalence of 15.1% in a series of 258 cases of children aged less than 10 years, who were admitted with a diagnosis of VL. This fact draws attention to the need to consider HLH triggered by VL, especially in patients with an unfavorable course during the specific treatment. However, in countries where VL is not endemic, the presence of secondary HLH is mostly triggered by viral infections, with the Epstein–Barr virus being the most frequent causative agent, with the worst prognosis.

In Brazil, pediatric patients have a higher prevalence of the association between VL and HLH compared to adults, which differs from the findings of studies conducted in other countries.

Literature data show that the main trigger for secondary HLH in childhood is viral infections, chiefly the Epstein–Barr virus, which was not observed in this study. During the study period, there was only one case of HLH secondary to this virus, which had an unfavorable course, only reverting with the use of chemotherapy. This patient was not included in this study.

The majority of the diagnosed patients were below two years of age, which is consistent with the findings of other studies. The mean weight showed no tendency or risk of malnutrition, unlike what has been observed in several previous studies on VL. There was a slight predominance of males over females, which is consistent with the findings of studies by Daher et al. and Scalzone et al. Moreover, the majority of the diagnosed patients inhabited urban areas, thereby confirming the process of urbanization of VL that has occurred since 1980.

All patients met five or six laboratory and clinical criteria for HLH and VL, with the maximum number of achievable criteria being six since the institution did not conduct research on NK cell activity or soluble CD25 dosage, which would have allowed for the achievement of eight possible criteria. However, HLH and VL were confirmed by the occurrence of hemophagocytosis in the bone marrow aspirate, along with serum triglycerides and ferritin levels, the latter being measurable up to 1,500 ng/dL.

Direct parasitological examination of the aspirated bone marrow material and the rapid test for VL (Kalazar detect or IT-Leish) were the specific tests used. The rapid test showed the best performance, being positive for almost all patients who were evaluated. It is important to highlight that the last five participants did not undergo the test due to the lack of the product.

The direct examination of bone marrow aspirate showed a similar positive response to that recorded in other studies, but contrasted with the low positivity found in cases of VL/HLH, as described by Gagnaire et al. The discrepancy in the direct examination is indicative of the relevance of the rapid test, which has high sensitivity and specificity, ease, and speed of execution, and therefore, is considered useful in patients whose diagnosis and treatment should be initiated as early as possible to avoid the complications that most often cause death.

Fever, hepatosplenomegaly, and pancytopenia were detected in all participants; nearly half presented with involvement of the three peripheral blood lineages, and all had anemia and thrombocytopenia. This high prevalence of clinical and laboratory changes could be explained by the etiopathogenesis of this association, which leads to an intense activation of monocytes and macrophages by cytokines produced by T lymphocytes in response to the infection. It is important to emphasize that the clinical and hemogram similarity between the two entities (fever, hepatosplenomegaly, pancytopenia) often hinders and delays the diagnosis, consequently affecting the treatment.

The changes described herein are consistent with those described in several other studies on this topic, as reported by Henter et al.

Complete remission of HLH with VL-specific therapy was observed in most patients. However, a considerable number of patients required the use of corticotherapy in anti-inflammatory (23.0%) or immunosuppressive (15.4%) doses.

In order to inhibit cytokine expression and suppress the excessive immune response, dexamethasone with a dose of 10 mg/m² of body surface was used as an immunosuppressive agent, as indicated by Gagnaire et al. The anti-inflammatory dose was 0.22 mg.kg⁻¹.day⁻¹ for 7 days. This drug was chosen because it can cross the blood–brain barrier, thereby suppressing inflammation in the central nervous system. Another intervention is to use
TABLE 1: Visceral leishmaniasis associated with hemophagocytic lymphohistiocytosis, criteria that defined the diagnosis and therapies performed in thirty-nine pediatric patients with an association of HLH/VL. Period from January 2012 to December 2017.

| Nº  | Age (years old) | Sex | Hemophagocytosis | Fever days | Hepatosplenomegaly | Cytopenia | Ferritin (years ng/mL) | Triglycerides mg/dL | Jaundice | T. He | T. Pla | T. PFC | Antibiotic therapy | Corticosteroid therapy | Clinical outcome |
|-----|----------------|-----|-------------------|------------|-------------------|-----------|------------------------|---------------------|-----------|-------|--------|--------|------------------|---------------------|-----------------|
| 1   | 4a10m          | F   | POS               | 13         | PRES              | Pa        | 519                    | 401                 | ABS       | R     | NR     | NR     | NR               | A                   | CURED           |
| 2   | 1a             | M   | NEG               | 13         | PRES              | Pa        | ≥ 1.500                | 556                 | ABS       | R     | R      | R      | A                | A                   | CURED           |
| 3   | 2a1m           | M   | POS               | 10         | PRES              | Pa        | ≥ 1.500                | 812                 | ABS       | R     | NR     | NR     | A                | A                   | CURED           |
| 4   | 11m            | M   | NEG               | 7          | PRES              | Pa        | 574                    | 580                 | ABS       | R     | R      | NR     | NR               | NR                | CURED           |
| 5   | 4a11m          | M   | POS               | 28         | PRES              | Bi        | ≥ 1.500                | 210                 | ABS       | NR    | NR     | NR     | AE               | A                   | CURED           |
| 6   | 2a3m           | M   | NR                | 30         | PRES              | Pa        | ≥ 1.500                | 270                 | ABS       | R     | R      | NR     | AE               | A                   | CURED           |
| 7   | 3a7m           | M   | NEG               | 20         | PRES              | Pa        | ≥ 1.500                | 443                 | ABS       | R     | NR     | NR     | A                | S                   | CURED           |
| 8   | 11m            | M   | NEG               | 8          | PRES              | Pa        | 512                    | 339                 | ABS       | R     | R      | NR     | A                | A                   | CURED           |
| 9   | 1a4m           | F   | NEG               | 90         | PRES              | Pa        | ≥ 1.500                | 309                 | ABS       | NR    | NR     | NR     | AE               | NR                 | CURED           |
| 10  | 1a3m           | F   | NEG               | 15         | PRES              | Bi        | ≥ 1.500                | 359                 | ABS       | R     | R      | NR     | NR               | NR                 | CURED           |
| 11  | 11m            | F   | POS               | 30         | PRES              | Bi        | 580                    | 1.620               | PRES      | NR    | NR     | NR     | AE               | S                   | CURED           |
| 12  | 2a3m           | M   | NEG               | 30         | PRES              | Bi        | ≥ 1.500                | 387                 | ABS       | R     | R      | NR     | A                | A                   | CURED           |
| 13  | 4a             | M   | NEG               | 30         | PRES              | Bi        | ≥ 1.500                | 442                 | ABS       | NR    | NR     | NR     | NR               | NR                 | CURED           |
| 14  | 4a5m           | F   | POS               | 15         | PRES              | Bi        | 830                    | 286                 | ABS       | NR    | NR     | NR     | NR               | NR                 | CURED           |
| 15  | 4a7m           | F   | POS               | 14         | PRES              | Bi        | 900                    | 300                 | ABS       | R     | R      | R      | A                | S                   | CURED           |
| 16  | 1a4m           | M   | POS               | 11         | PRES              | Bi        | ≥ 1.500                | 291                 | ABS       | NR    | NR     | NR     | A                | A                   | CURED           |
| 17  | 5m             | F   | POS               | 15         | PRES              | Pa        | 542                    | 280                 | ABS       | R     | R      | NR     | A                | NR                 | CURED           |
| 18  | 9m             | M   | NEG               | 7          | PRES              | Bi        | 879                    | 268                 | ABS       | NR    | NR     | NR     | AE               | A                   | CURED           |
| 19  | 4a10m          | F   | NR                | 15         | PRES              | Pa        | ≥ 1.500                | 332                 | ABS       | R     | R      | NR     | A                | A                   | CURED           |
| 20  | 1a6m           | M   | POS               | 15         | PRES              | Bi        | ≥ 1.500                | 467                 | ABS       | R     | R      | NR     | A                | NR                 | CURED           |
| 21  | 2a             | M   | NEG               | 8          | PRES              | Bi        | ≥ 1.500                | 323                 | ABS       | NR    | NR     | NR     | NR               | A                   | CURED           |
| 22  | 6a             | M   | NEG               | 120        | PRES              | Pa        | 1.100                  | 267                 | ABS       | R     | R      | NR     | NR               | NR                 | CURED           |
| 23  | 3a6m           | M   | POS               | 15         | PRES              | Bi        | ≥ 1.500                | 273                 | ABS       | NR    | NR     | NR     | NR               | NR                 | CURED           |
| 24  | 6a1m           | F   | POS               | 15         | PRES              | Bi        | ≥ 1.500                | 359                 | ABS       | NR    | NR     | NR     | S                | M                   | CURED           |
| 25  | 1a3m           | F   | NEG               | 60         | PRES              | Pa        | ≥ 1.500                | 391                 | ABS       | NR    | NR     | NR     | A                | NR                 | CURED           |
| 26  | 1a             | F   | NEG               | 20         | PRES              | Bi        | ≥ 1.500                | 301                 | ABS       | NR    | NR     | NR     | NR               | NR                 | CURED           |
| 27  | 9a2m           | M   | POS               | 30         | PRES              | Bi        | ≥ 1.500                | 295                 | ABS       | NR    | NR     | NR     | NR               | CURED             |
| 28  | 2a6m           | M   | POS               | 9          | PRES              | Pa        | ≥ 1.500                | 254                 | ABS       | R     | R      | NR     | A                | S                   | CURED           |
| 29  | 1a1m           | F   | NEG               | 7          | PRES              | Bi        | 1.124                  | 349                 | ABS       | NR    | NR     | NR     | A                | NR                 | CURED           |
| 30  | 1a10m          | F   | NEG               | 20         | PRES              | Bi        | 1.297                  | 590                 | PRES      | R     | R      | NR     | AE               | NR                 | CURED           |
| 31  | 9m             | M   | NEG               | 15         | PRES              | Bi        | 550                    | 397                 | ABS       | R     | R      | NR     | NR               | NR                 | CURED           |
| 32  | 4a4m           | F   | NEG               | 30         | PRES              | Bi        | ≥ 1.500                | 337                 | ABS       | NR    | NR     | NR     | AE               | CURED             |
| 33  | 2a6m           | M   | NEG               | 15         | PRES              | Pa        | ≥ 1.500                | 489                 | ABS       | R     | R      | NR     | NR               | NR                 | CURED           |
| 34  | 1a             | M   | NEG               | 15         | PRES              | Bi        | 1.461                  | 466                 | ABS       | NR    | NR     | NR     | NR               | NR                 | CURED           |
| 35  | 3a             | F   | NEG               | 9          | PRES              | Bi        | ≥ 1.500                | 332                 | ABS       | NR    | NR     | NR     | NR               | NR                 | CURED           |
| 36  | 4a4m           | F   | POS               | 21         | PRES              | Bi        | 887                    | 361                 | ABS       | NR    | NR     | NR     | NR               | CURED             |
| 37  | 1a8m           | F   | POS               | 60         | PRES              | Pa        | NR                     | 397                 | ABS       | R     | R      | NR     | A                | A                   | CURED           |
| 38  | 2a1m           | F   | POS               | 20         | PRES              | Pa        | ≥ 1.500                | 263                 | ABS       | NR    | NR     | NR     | NR               | NR                 | CURED           |
| 39  | 8a2m           | M   | POS               | 20         | PRES              | Pa        | 673                    | 368                 | ABS       | R     | R      | NR     | AE               | NR                 | CURED           |

Source: Prepared by the author, 2018.

VL: visceral leishmaniasis; HLH: hemophagocytic lymphohistiocytosis; M: male; F: female; POS: positive; NEG: negative; R: performed; NR: not performed; PRES: present; ABS: absent; Bi: bicytopenia; Pa: pancytopenia; T. He, Pla, PFC: transusions of packed red blood cells, platelets and fresh frozen plasma; AE: empirical antibiotic therapy; AI: antibiotic therapy with identified focus; A: anti-inflammatory dose; S: immunosuppressive dose.
prednisone or prednisolone at the dose of 1 mg.kg⁻¹.day⁻¹ while the signs of HLH severity persist, especially coagulation disorders. Moreover, Imashuku et al. have recommended using water-soluble corticosteroids (dexamethasone or methylprednisolone or prednisolone) as the first line of treatment. Patients classified as low risk for HLH have shown rapid healing with corticotherapy alone or in association with intravenous immunoglobulin.

In the present study, all patients were followed up for twelve months after treatment, as suggested by other researchers. The one-year follow-up was scheduled after hospital discharge and was already part of the routine of this service. All patients were cured of VL and its complications, and the use of other therapies was not necessary, as also reported by Henter et al.

Significant improvement in prognosis has been achieved through the incorporation of supportive intensive care at the onset of the disease, including the control of DIC and opportunistic infections associated with neutropenia, and the prompt introduction of immunosuppression to control the cytokine storm.

Patients in this study were not tested for fibrinogen levels or CD25 and NK cell activity. Despite the limitations, this study contemplates the largest series of cases recorded so far on the association between VL and HLH, which seems to be more frequent than reported by other studies, but with lower mortality.

HLH associated with childhood VL in endemic areas is common and should always be considered since it is a potentially fatal condition.

In the present study, the majority of patients with the VL/HLH association, compared to those with VL alone, were younger than 3 years old and living in urban areas. All had fever, hepatosplenomegaly, anemia, and thrombocytopenia. The clinical manifestations were more exuberant, often showing signs of severity, such as hemorrhage in one or more sites, edema, toxic-infectious state, and jaundice. Additionally, aminotransferases were often elevated. Transfusions of blood products, antibiotics, and corticosteroids were frequently used, in addition to specific treatment for VL.

Early diagnosis and treatment may lead to a cure for HLH. Medical professionals aiding in these areas should be prepared for the diagnostic suspicion when faced with clinical and laboratory conditions that characterize VL (fever, hepatosplenomegaly, and changes in one or more peripheral blood lines) and HLH (Added to the VL signals, elevated serum ferritin levels > 500 µg/L, triglycerides > 265 mg/dL, or fibrinogen < 150 mg/dL). Figures of hemophagocytosis in the bone marrow are not exclusive to HLH.

CONCLUSION

In Brazil, HLH is a common and potentially fatal complication of VL, which pediatricians should be aware of. The diagnosis of HLH should be considered in patients with severe VL, especially if there is evidence of liver involvement. Although the syndrome may be inapparent and healed with anti-parasitic therapy of leishmaniasis, this may not always occur. HLH has been reported to cause high lethality; therefore, immunosuppressive or anti-inflammatory therapy should be instituted immediately to avoid an irreversible outcome. Taking into consideration the use of corticotherapy, further studies are needed to indicate the best option. Liposomal Amphotericin B is effective and well-tolerated when used for a short period.

ACKNOWLEDGEMENTS

We are grateful to the Hospital Universitário Clemente de Faria/UNIMONTES for their cooperation and logistic support.

AUTHORS’ CONTRIBUTIONS

FHGC: Writing of the first version of the manuscript, selection and sampling analysis, and research on theoretical and methodological frameworks; JFL, LFT, APC, and SFGC: Analysis, discussion, writing, and review.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

REFERENCES

1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PloS one. 2012;7(5):e35671.

2. Ministério da Saúde [Internet]. DATASUS - Tecnologia da informação do SUS-Leishmaniose Visceral - casos confirmados notificados no sistema de informação de agravos de notificação SINAN-Brasil. 2005-2015 [acesso em 22 de novembro de 2016]. Disponível em: http://tabnet.datasus.gov.br/cgi/tabcgi.exe/sinanet/cnv/leishvnmv.def.

3. Cancado GG, Freitas GG, Faria FH, de Macedo AV, Nobre V. Hemophagocytic lymphohistiocytosis associated with visceral leishmaniasis in late adulthood. Am J Trop Med Hyg. 2013;88(3):575-7.

4. Rajagopala S, Dutta U, Chandra KS, Bhatia P, Varma N, Kochhar R. Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis-case report and systematic review. J Infect. 2008;56(5):381-8.

5. Henter JI, Arico M, Elinder G, Imashuku S, Janka G. Familial hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998;12(2):417-33.

6. Janka GE. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr. 1983;140(3):221-30.

7. Ferreira DGR, Rezende PV, Murao M, Viana MB, Oliveira B. Hemophagocytic lymphohistiocytosis: a case series of a Brazilian institution. Rev. Bras. Hematol. Hemoter. 2014;36(6):437-441.

8. George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014;5:69-86.

9. Henter JI, Horne A, Arico M, Egelert RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-31.

10. Tunc B, Ayata A. Hemophagocytic syndrome: a rare life-threatening complication of visceral leishmaniasis in a young boy. Pediatr Hematol Oncol. 2001;18(8):531-6.

11. Scalzone M, Ruggiero A, Mastrangelo S, Trombatore G, Ridola V, Maurizi P, et al. Hemophagocytic lymphohistiocytosis and visceral leishmaniasis in children: case report and systematic review of literature. J Infect Dev Ctries. 2016;10(1):103-8.

12. Bode SF, Bogdan C, Beutel K, Behnisch W, Greiner J, Henning S, et al. Hemophagocytic lymphohistiocytosis in imported pediatric visceral leishmaniasis in a nonendemic area. J Pediatr. 2014;165(1):147-53.
13. Ranjan P, Kumar V, Ganguly S, Sukumar M, Sharma S, Singh N, et al. Hemophagocytic Lymphohistiocytosis Associated with Visceral Leishmaniasis: Varied Presentation. Transfus de sangue indiano J Hematol. 2016;32(Suppl 1):351-4.

14. Gargouri L, Maalej B, Kassar O, Weli M, Safi F, Mejdoub I, et al. Hemophagocytic Syndrome Secondary to Visceral Leishmaniasis in a 5-year-old boy. JI M Sfax. 2016(23):48-51.

15. Soner SCB, İlknur K, Süheyl A, Tuba T, Yusuf ZD. A rare hematological complication of visceral leishmaniasis: hemophagocytic syndrome. Cukurova Med J. 2016;41(01):161-3.

16. Matnani R, Ganapathi KA. Hemophagocytic lymphohistiocytosis associated with visceral leishmaniasis. Blood. 2016;127(4):513.

17. Khalilzadeh S, Hassanazad M, Fard EH, Dorudinia A, Velayati AA. Visceral leishmaniasis in two brothers: diagnostic dilemma due to hemophagocytic syndrome. Tanaftos. 2013;12(2):53-5.

18. Daher EF, Lima LL, Vieira AP, Nascimento LS, Soares DS, Abreu KL, et al. Hemophagocytic Syndrome in Children With Visceral Leishmaniasis. Pediatr Infect Dis J. 2015;34(12):1311-4.

19. Rouphael NG, Talati NJ, Vaughan C, Cunningham K, Moreira R, Gould C. Infections associated with haemophagocytic syndrome. Lancet Infect Dis. 2007;7(12):814-22.

20. Imashuku S, Hibi S, Tabata Y, Sako M, Sekine Y, Hirayama K, et al. Biomarker and morphological characteristics of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Med Pediatr Oncol. 1998;31(3):131-7.

21. Gagnaire MH, Galambrun C, Stephan JL. Hemophagocytic syndrome: A misleading complication of visceral leishmaniasis in children—a series of 12 cases. Pediatrics. 2000;106(4):1-6.

22. Celik U, Alabaz D, Alhan E, Bayram I, Celik T. Diagnostic dilemma in an adolescent boy: hemophagocytic syndrome in association with kala azar. Am J Med Sci. 2007;334(2):139-41.

23. Agarwal S, Narayan S, Sharma S, Kahkashan E, Patwari AK. Hemophagocytic syndrome associated with visceral leishmaniasis. Indian J Pediatr. 2006;73(5):445-6.

24. Malafaia G. Leishmaniose visceral e desnutrição: uma relação ainda muito negligenciada. Carta ao Editor. Rev Soc Bras Med Trop. 2010;43(4):478-79.

25. Werneck G. Leishmaniose visceral no Brasil: para onde vamos? [Internet]. 2017. Sociedade Brasileira de Medicina Tripical; 2017 [citado em 22 nov 2016] Disponível em: https://www.sbmt.org.br/portal/visceral-leishmaniasis-in-brazil-where-are-we-going/?lang=en.

26. Carvalho SF, Lemos EM, Corey R, Dietze R. Performance of recombinant K39 antigen in the diagnosis of Brazilian visceral leishmaniasis. Am J Trop Med Hyg. 2003;68(3):321-4.

27. Maia Z, Lirio M, Mistro S, Mendes CM, Mehta SR, Badaro R. Comparative study of rK39 Leishmania antigen for serodiagnosis of visceral leishmaniasis: systematic review with meta-analysis. PLoS Negl Trop Dis. 2012;6(1):e1484.

28. Wilson ME, Jeronimo SM, Pearson RD. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog. 2005;38(4):147-60.

29. Granert C, Elinder G, Ost A, Henter JI. Kala-azar in a one-year-old Swedish child. Diagnostic difficulties because of active hemophagocytosis. Acta Paediatr. 1993;82(9):794-6.

30. Sotoca FJV VL, Lillo ML, Mialdea OG, Romero MCC. Síndrome hemofagocítico secundario a leishmaniasis visceral. An Pediatr (Barc). 2008;69(1):46-8.

31. Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000;88(8):1964-9.

32. Borges MM, Pranchevicius MC, Noronha EF, Romero GA, Carranza-Tamayo CO. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil. Rev Soc Bras Med Trop. 2017;50(1):67-74.

33. Imashuku S, Teramura T, Morimoto A, Hibi S. Recent developments in the management of haemophagocytic lymphohistiocytosis. Expert Opin Pharmacother. 2001;2(9):1437-48.

34. Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunotherapy and bone marrow transplantation. Blood. 2002;100(7):2367-73.